[Advances and principles in tuberculostatic therapy].
D000328:Adult; D000636:Aminosalicylic Acids / Q000008:administration & dosage; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003523:Cycloserine / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000008:administration & dosage; D005000:Ethionamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D007612:Kanamycin / Q000008:administration & dosage; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010670:Phenylthiourea / Q000008:administration & dosage / Q000031:analogs & derivatives; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage; D013882:Thiosemicarbazones / Q000008:administration & dosage; D014376:Tuberculosis / Q000188:drug therapy*; D014756:Viomycin / Q000008:administration & dosage
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D007612:Kanamycin; D010670:Phenylthiourea; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin
Fortschritte und Grundsätze der tuberkulostatischen Behandlung.